Tim* has experience on a wide range of antitrust, health care, telecommunication, and litigation matters in federal court and government investigations before the Department of Justice and Federal Trade Commission. He has assisted clients in responding to agency demands and helped guide clients through the Hart-Scott-Rodino merger review process. Tim has also advised clients on the potential antitrust implications of proposed joint ventures. In addition to his antitrust practice, Tim is active in the firm's pro bono program, including working with a pro bono client to draft an amicus brief for the Supreme Court.
Prior to joining the firm, Tim served for four years as a staff attorney in the Health Care Division of the Federal Trade Commission's Bureau of Competition. During his time with the FTC, Tim conducted and defended numerous investigational hearings and depositions of fact and expert witnesses, participated in pharmaceutical reverse payment litigation in federal district court, and was selected to lead a seminar presented to attorneys and economists on investigational techniques. Tim also conducted investigations into physician joint ventures and reviewed physicians' clinical integration programs with an eye toward antitrust enforcement. Tim's work with the FTC also involved reviewing and analyzing pharmaceutical patent settlement filings under the Medicare Modernization Act (MMA), in addition to then creating a comprehensive database in which to house the filings.
While in law school, Tim served as the Senior Notes Editor for the William & Mary Bill of Rights Journal. His student note was published in the journal in Spring 2009.
•Mintz Levin Files Amicus Brief in Pivotal First Amendment Case, Elonis v. United States, (10.07.2014)
Awards & Recognitions
•Phi Beta Kappa
•Sharpe Community Scholar, College of William & Mary
•Alumni Prize in Business, College of William & Mary
•Co-author, What Pom Wonderful v. FTC Means for Class Actions, Law360 (02.19.2015)
•Co-author, FTC Tastes Sweet Victory in POM Wonderful Deceptive Advertising Appeal, Antitrust Alert (02.17.2015)
•Co-author, DOJ Releases Electrifying New Guidance on Standard-Essential Patent Policy, Antitrust Alert (02.11.2015)
•Co-author, An Early Test of Antitrust Ramifications of FDA's REMS, Law360 (01.27.2015)
•Co-author, Medtronic Deal Highlights FTC Focus On Future Competition, Law360 (01.22.2015)
•Co-author, District Court Permits Section 2 Claim to Proceed Against Pharmaceutical Manufacturer for Denying Generic Rival Access to Branded Drug Samples, Antitrust Alert (01.09.2015)
•Co-author, Medtronic and Covidien's Blockbuster Medical Products Merger Clears FTC Antitrust Review with Divestiture, Antitrust Advisory (12.05.2014)
•Author, Milk Processors Soured After Rare Monopsony Ruling, Law360 (06.23.2014)
•Author, Milk Processors Soured After Federal District Court Rules They Must Face Monopsonization Claims at Trial, Antitrust Alert (06.20.2014)
•Co-author, Antitrust Hospital Merger Policy Gets a Judicial Boost - Sixth Circuit Upholds FTC Decision Challenging Hospital Merger, Antitrust Alert (04.23.2014)
•Co-author, NCAA Player Antitrust Class Action Advances to Final Round, Law360 (04.22.2014)
•Co-author, Busting Brackets: District Court Rejects NCAA's Summary Judgment Motion and Allows Student-Athletes' Suit for Publicity Compensation to March to Trial, Antitrust Alert (04.18.2014)
•Co-author, FTC Check-Up on Health Care Trends Reveals New Competitive Wrinkles-Highlights from the FTC Workshop “Examining Health Care Competition, Health Lawyers Weekly (04.11.2014)
•Co-author, FTC Check-Up on Health Care Trends Reveals New Competitive Wrinkles, Antitrust Advisory (03.27.2014)
•Author, Note, The Dormant Commerce Clause: Adopting a New Standard and a Return to Principle, 17 WM. & MARY BILL RTS. J. 1243 (2009)